ATE183774T1 - Löslicher interferon-rezeptor, seine herstellung und anwendung - Google Patents

Löslicher interferon-rezeptor, seine herstellung und anwendung

Info

Publication number
ATE183774T1
ATE183774T1 AT94116559T AT94116559T ATE183774T1 AT E183774 T1 ATE183774 T1 AT E183774T1 AT 94116559 T AT94116559 T AT 94116559T AT 94116559 T AT94116559 T AT 94116559T AT E183774 T1 ATE183774 T1 AT E183774T1
Authority
AT
Austria
Prior art keywords
preparation
application
interferon receptor
soluble interferon
soluble
Prior art date
Application number
AT94116559T
Other languages
English (en)
Inventor
Carolina Abramovich
Edward Ratovitski
Michel Revel
Original Assignee
Yeda Res & Dev
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Yeda Res & Dev filed Critical Yeda Res & Dev
Application granted granted Critical
Publication of ATE183774T1 publication Critical patent/ATE183774T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
    • G01N33/6866—Interferon
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Molecular Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cell Biology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Urology & Nephrology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pathology (AREA)
  • Oncology (AREA)
  • Biophysics (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Toxicology (AREA)
  • Genetics & Genomics (AREA)
  • Transplantation (AREA)
  • Neurology (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
AT94116559T 1993-10-24 1994-10-20 Löslicher interferon-rezeptor, seine herstellung und anwendung ATE183774T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
IL10737893A IL107378A (en) 1993-10-24 1993-10-24 SOLUBLE INTERFERON alpha-RECEPTOR, ITS PREPARATION AND USE

Publications (1)

Publication Number Publication Date
ATE183774T1 true ATE183774T1 (de) 1999-09-15

Family

ID=11065371

Family Applications (1)

Application Number Title Priority Date Filing Date
AT94116559T ATE183774T1 (de) 1993-10-24 1994-10-20 Löslicher interferon-rezeptor, seine herstellung und anwendung

Country Status (13)

Country Link
US (1) US5643749A (de)
EP (1) EP0679717B1 (de)
JP (3) JPH07236488A (de)
AT (1) ATE183774T1 (de)
AU (1) AU684103B2 (de)
CA (1) CA2134030C (de)
DE (1) DE69420251T2 (de)
DK (1) DK0679717T3 (de)
ES (1) ES2140489T3 (de)
GR (1) GR3031354T3 (de)
IL (1) IL107378A (de)
SI (1) SI0679717T1 (de)
ZA (1) ZA948345B (de)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2133285T3 (es) * 1991-04-17 1999-09-16 Medisup Int Nv Polipeptidos hidrosolubles que tienen una alta afinidad para los interferones alfa y beta.
US5780027A (en) * 1995-07-14 1998-07-14 Meiogen Biotechnology Corporation Methods of treatment of down syndrome by interferon antagonists
US7063958B1 (en) * 1996-01-16 2006-06-20 The Rockefeller University Nucleic acids db, the receptor for leptin
ATE285076T1 (de) * 1996-08-19 2005-01-15 Shaker Ghassan I Verwendung von molt4 cd69 expression zur bestimmung der anwesenheit und der aktivität von interferoninhibitoren
US20020119129A1 (en) 1997-01-15 2002-08-29 Yeda Research And Development Co. Ltd. Novel IFN receptor 1 binding proteins, DNA encoding them, and methods of modulating cellular response to interferons
KR100591988B1 (ko) * 1997-01-15 2006-06-21 예다 리서치 앤드 디벨럽먼트 캄파니 리미티드 신규한 인터페론 수용체 1 결합 단백질들, 이들을 코딩하는디엔에이 및 인터페론에 대한 세포성 반응을 조절하는방법
EP1780277A1 (de) * 1997-01-15 2007-05-02 Yeda Research And Development Company, Ltd. IFN Rezeptor 1 bindende Proteine, dafür kodierende DNA und Verfahren zur Regulierung der zellulären Antwort auf Interferone
NZ504771A (en) 1997-12-19 2002-09-27 Applied Research Systems IFNAR2/ INFcomplex for prolonging the in vivo effects of type I interferon (INF)
AUPP670698A0 (en) * 1998-10-23 1998-11-19 Monash University A method of regulation
UA74557C2 (en) 1999-09-03 2006-01-16 Applied Research Systems A method for producing a heterologous secreted protein from chinese hamster ovaries cells grown on microcarriers
IL147414A0 (en) 2001-12-31 2002-08-14 Yeda Res & Dev Ifnar2 mutants, their production and use
EP1893646A2 (de) * 2005-06-22 2008-03-05 Genentech, Inc. Verfahren und zusammensetzungen für ifnar2-targeting
RU2411039C2 (ru) * 2007-12-26 2011-02-10 Валентина Васильевна Малиновская Иммунокорригирующее средство для лечения заболеваний вирусной этиологии
WO2013003475A1 (en) 2011-06-27 2013-01-03 Cellscript, Inc. Inhibition of innate immune response
ES2470816B1 (es) * 2012-11-22 2015-04-01 Servicio Andaluz De Salud Proteína recombinante y usos en el diagnóstico de la esclerosis múltiple
CA3029627A1 (en) 2016-07-01 2018-01-04 Resolve Therapeutics, Llc Optimized binuclease fusions and methods
CA3073537A1 (en) 2017-08-22 2019-02-28 Sanabio, Llc Soluble interferon receptors and uses thereof

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU625866B2 (en) * 1989-04-19 1992-07-16 F. Hoffmann-La Roche Ag Soluble interferon-gamma receptors and methods for their production
IL91562A0 (en) * 1989-09-07 1990-04-29 Yeda Res & Dev Interferon-gamma receptor fragment and its production
ES2133285T3 (es) * 1991-04-17 1999-09-16 Medisup Int Nv Polipeptidos hidrosolubles que tienen una alta afinidad para los interferones alfa y beta.
IL106591A (en) * 1992-09-03 2008-03-20 Yeda Res & Dev Interferon alpha/beta binding protein, its preparation and pharmaceutical compositions containing it

Also Published As

Publication number Publication date
EP0679717A2 (de) 1995-11-02
SI0679717T1 (en) 1999-12-31
JP2005130865A (ja) 2005-05-26
ZA948345B (en) 1995-07-17
IL107378A (en) 2005-05-17
ES2140489T3 (es) 2000-03-01
EP0679717A3 (de) 1997-04-23
CA2134030A1 (en) 1995-04-25
DK0679717T3 (da) 2000-03-13
GR3031354T3 (en) 2000-01-31
US5643749A (en) 1997-07-01
JP2007097593A (ja) 2007-04-19
AU684103B2 (en) 1997-12-04
JPH07236488A (ja) 1995-09-12
DE69420251T2 (de) 2000-05-11
EP0679717B1 (de) 1999-08-25
DE69420251D1 (de) 1999-09-30
IL107378A0 (en) 1994-01-25
CA2134030C (en) 2010-06-29
AU7597794A (en) 1995-05-11

Similar Documents

Publication Publication Date Title
ATE183774T1 (de) Löslicher interferon-rezeptor, seine herstellung und anwendung
DE10199018I1 (de) Thiazolidindion-Derivate deren Herstellung und Anwendung
DE69027057D1 (de) Retinal, dessen Derivate und deren therapeutische Verwendung
ATE224910T1 (de) Derivate von dolestatin, deren herstellung und verwendung
ATE211467T1 (de) 4-amino-derivate der mycophenolsäure mit immun suppressiver wirkung
EE9800459A (et) Spiro-piperidiini derivaadid ja nende kasutamine terapeutiliste toimeainetena
FI950458A7 (fi) N-(3-aminopropyyli)-N-fenyyli-5,6,7,8-tetrahydronaftalen-2-karboksamidijohdannaiset, niiden valmistus ja terapeuttinen käyttö
DE68913739D1 (de) Kosmetische und hautbehandlungs-zusammensetzungen.
ATE218567T1 (de) 1h-pyrido(3,4-b)indolcarboxamidderivate, ihre herstellung und therapeutische verwendung
DE3779250D1 (de) Acrylcopolymere, diese enthaltende hautschutzmittel und ihre anwendung.
ATE226584T1 (de) 4-oxo-3,5-dihydro-4h-pyridazino(4,5-b)indol-1- acetamid-derivate, ihre herstellung und therapeutische anwendung
FI892344A7 (fi) 6-fenyyli-3-piperatsinyylialkyyli-1H,3H-pyrimidiini-2,4-dionin johdannaisia, niiden valmistus ja niiden terapeuttinen käyttö
DE69330075D1 (de) Oxazolinderivate, ihre Herstellung und Anwendung
DE59100496D1 (de) Verwendung von selektiv hydrierten Styrol-Butadien-Copolymerisaten in kosmetischen und pharmazeutischen Zubereitungen.
ATE184005T1 (de) Oxazolidinone derivate, ihre herstellung und ihre therapeutische verwendung
DE69408211D1 (de) Polyfunktionelle Polyisobutylene, ihre Herstellung, ihre Formulierung und ihre Anwendung
DE69217783D1 (de) 3-Phenoxybenzyl(iden)pyrrolidin-Derivate, deren Herstellung und deren Verwendung als muskarin-cholinerge Mittel
EE03687B1 (et) Furaandiarüülmetülideeni derivaadid, nende valmistamise meetod ja kasutamine teraapias
EE9900135A (et) N-(2-bensotiasolüül)-1-piperidiinetaanamiini derivaadid, nende valmistamine ja kasutamine raviks
ATE210126T1 (de) 4-amino-6-substituierte mycophenolsäurederivate mit immunsuppressiver wirkung
ATE205841T1 (de) Derivate von 5-naphthalin-1-yl-1,3-dioxanen, ihre herstellung und therapeutische anwendung
DE3788888D1 (de) Perhydrothiazepin- und Perhydroazepinderivate, ihre Herstellung und ihre therapeutische Verwendung.
FR2753196B1 (fr) Derives d'indazole tricyclique, leur preparation et leur application en therapeutique
DE69015602D1 (de) Oxadiazolinon-Derivat, seine Herstellung und seine Verwendung.
DE69001439D1 (de) Herstellung von kuenstlichen zaehnen und kronen.

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification